Salarius Pharmaceuticals ...

NASDAQ: SLRX · Real-Time Price · USD
5.76
0.14 (2.49%)
At close: Aug 26, 2025, 3:58 PM
6.25
8.51%
Pre-market: Aug 27, 2025, 07:04 AM EDT

Salarius Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 4.43K n/a n/a n/a 17.89K n/a n/a n/a n/a n/a n/a n/a n/a n/a 571.39K 1.27M
Cost of Revenue
1.11K 1.11K 2.21K 1.1K 1.11K 1.11K 1.1K 5.61K 1.67K 1.67K 1.67K 1.67K 2.92M 4.44M 1.85M 4.8K 2.1M 1.74M
Gross Profit
-1.11K -1.11K 2.21K -1.1K -1.11K -1.11K 16.79K -5.61K -1.67K -1.67K -1.67K -1.67K -2.92M -4.44M -1.85M -4.8K -1.52M -471.83K
Operating Income
-957.83K -1.72M -1.49M -1.01M -1.47M -1.77M -970.7K -2.53M -3.97M -5.42M -6.48M -5.62M -4.76M -6.12M -4.14M -3.75M -3.12M -1.8M
Interest Income
7.74K 9.16K 24.78K 34.35K 43.08K 56.33K 88.91K 89.37K n/a 79.89K n/a 78.61K n/a n/a n/a n/a n/a n/a
Pretax Income
-957.83K -1.71M -1.46M -972.12K -1.42M -1.72M -881.8K -2.44M -3.88M -5.34M -6.37M -14.41M -4.72M -6.11M -4.1M -3.74M -3.07M -1.85M
Net Income
-957.83K -1.71M -1.46M -972.12K -1.42M -1.72M -881.8K -2.44M -3.88M -5.34M -6.37M -14.41M -4.72M -6.11M -4.1M -3.74M -3.07M -1.85M
Selling & General & Admin
849.18K 1.64M 1.31M 869.24K 1.25M 1.53M 910.75K 1.5M 1.62M 1.7M 1.79M 1.83M 1.84M 1.68M 1.45M 1.73M 1.59M 1.33M
Research & Development
116.38K 75.53K 175.34K 137.23K 214.45K 243K 59.95K 1.04M 2.35M 3.73M 4.69M 3.79M 2.92M 4.44M 2.7M 2.02M 2.1M 1.74M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
965.57K 1.72M 1.49M 1.01M 1.47M 1.77M 970.7K 2.53M 3.97M 5.42M 6.48M 5.62M 4.76M 6.12M 4.14M 3.75M 3.69M 3.07M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.25K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
965.57K 1.72M 1.49M 1.01M 1.47M 1.77M 970.7K 2.53M 3.97M 5.42M 6.48M 5.62M 4.76M 6.12M 4.14M 3.75M 3.69M 3.07M
Income Tax Expense
n/a n/a n/a n/a n/a n/a -5 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
142.23K 111.48K 64.47K 85.89K 40.23K 35.13K 32.98K 31.42K 22.69K 20.03K 18.83K 18.82K 17.89K 15.5K 15.15K 15.01K 14.94K 10.23K
Shares Outstanding (Diluted)
142.23K 111.48K 64.47K 85.89K 40.23K 35.13K 32.98K 31.44K 22.69K 20.03K 18.87K 18.82K 17.93K 15.5K 15.15K 15.01K 14.99K 10.23K
EPS (Basic)
-6.75 -15.45 -22.8 -11.4 -35.55 -49.05 -26.85 -78.15 -171.75 -267.6 -43.2 -769.2 -270 -396 -270 -250.8 -210 -180
EPS (Diluted)
-6.75 -15.45 -22.8 -11.4 -35.55 -49.05 -26.85 -78.15 -171.75 -267.6 -43.2 -769.2 -270 -396 -270 -250.8 -210 -180
EBITDA
-957.83K -1.71M -1.49M -1.01M -1.47M -1.77M -969.6K -2.53M -3.97M -5.42M -6.48M -5.62M -4.76M -6.11M -4.14M -3.74M -3.11M -1.8M
EBIT
-957.83K -1.71M -1.49M -1.01M -1.47M -1.77M -970.7K -2.53M -3.97M -5.42M -6.48M -5.62M -4.76M -6.12M -4.14M -3.75M -3.12M -1.8M
Depreciation & Amortization
n/a 1.11K 1.11K 1.1K 1.11K 1.11K 1.1K 5.61K 1.67K 1.67K 1.67K 1.67K 1.67K 4.8K 4.8K 4.8K 4.8K 4.79K